Clinical Efficacy Comparison Of Saccharomyces Boulardii And Lactic Acid As Probiotics In Acute Pediatric Diarrhea

Asmat, Shakila; Shaukat, Fouzia; Asmat, Raheela; Bakhat, Hafiz Faiq Siddique Gul; Asmat, Tauseef M

doi:10.29271/jcpsp.2018.03.214

Cited by 10 publications

(12 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Probiotics in the pediatric population have been widely studied in the prevention and treatment of diarrheal diseases [ 15 ]. S. boulardii is a nonpathogenic probiotic yeast that is tolerated with gastric acid and antibiotics [ 16 ]. S. boulardii has been reported to reduce signs of diarrhea related to or caused by various factors in animals and humans [ 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Qiweibaizhu Decoction Treats Diarrheal Juvenile Rats by Modulating the Gut Microbiota, Short-Chain Fatty Acids, and the Mucus Barrier

Sun

Yang

Lin

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Qiweibaizhu decoction (QBD), a classic Chinese herbal formula, has been widely used for treating diarrhea in infants and children with spleen deficiency syndrome for centuries, but its mechanism of action remains unclear. The gut microbiota, short-chain fatty acids (SCFAs), and intestinal mucus are closely associated with diarrhea. Methods. In this study, the composition of the gut microbiota in diarrheal rats was analyzed by 16S rDNA amplicon sequencing. The concentrations of colon SCFAs were determined using gas chromatography-mass spectrometry (GC-MS). The expression of mucin 2 (MUC2) in the colon was detected by immunofluorescence. Results. Diarrhea significantly changed the diversity and structure of the gut microbiota and disrupted the mucus barrier in juvenile rats. QBD did not significantly change the diversity and structure of the intestinal flora, but it enhanced the increasing tendencies of Verrucomicrobia and Akkermansia and decreased the abundance of Turicibacter ( P = 0.037 ) and Flavonifractor ( P = 0.043 ). QBD tends to repair the mucus layer and promote MUC2 expression in juvenile rats with diarrhea. Moreover, S. boulardii significantly increased the abundance of Parasutterella ( P = 0.043 ). In addition, QBD treatment tends to increase the propionic acid concentration during diarrhea, but its levels of acetic acid, propionic acid, butyric acid, and total SCFAs were lower than those in the S. boulardii group. Conclusion. S. boulardii significantly increased the abundance of Parasutterella, leading to increased production of acetic acid, propionic acid, and butyric acid, consequently leading to alleviation of diarrhea. In comparison, QBD affected diarrhea via regulation of the intestinal flora, especially by increasing the abundance of Verrucomicrobia and Akkermansia, resulting in mucus barrier repair, protection of the intestines, and treatment of diarrhea.

show abstract

Section: Introductionmentioning

confidence: 99%

Qiweibaizhu Decoction Treats Diarrheal Juvenile Rats by Modulating the Gut Microbiota, Short-Chain Fatty Acids, and the Mucus Barrier

Sun

Yang

Lin

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…22 Probiotic such as, saccharomyces boulardii group, has significantly higher efficacy rate (45%) compared to lactic acid producing probiotic (26%). 23 This was also shown in reducing duration of diarrhea in children (3 months to 5 years) when administered (SB) for 5 days than control group. 24 Mean number of stools in children was significantly low in those patients who were treated with combination of probiotic (lactobacillus rhamnosus) with ORS than those who were treated with ORS only in acute diarrhea in only age group 12.21 to 36 months.…”

Section: Discussionmentioning

confidence: 82%

The Use of Probiotic with ORS and ORS Only in Children with Acute Diarrhea

Ali

2019

J Coll Physicians Surg Pak

View full text Add to dashboard Cite

show abstract

“…Based on their capabilities to resist both acid and bile, Dh25 and Sc16 were chosen as probiotic candidates to be tested on our in vivo model. The well-known probiotic Sb1079 was included as the control strain [ 44 , 45 , 46 , 47 ]. Usually, the acid tolerance test is performed at pH 3, but a pH value of 2.5 is more selective [ 48 ].…”

Section: Resultsmentioning

confidence: 99%

Investigation into In Vitro and In Vivo Caenorhabditis elegans Models to Select Cheese Yeasts as Probiotic Candidates for their Preventive Effects against Salmonella Typhimurium

et al. 2020

View full text Add to dashboard Cite

The design of multiscale strategies integrating in vitro and in vivo models is necessary for the selection of new probiotics. In this regard, we developed a screening assay based on the investigation of the potential of yeasts from cheese as probiotics against the pathogen Salmonella Typhimurium UPsm1 (ST). Two yeasts isolated from raw-milk cheese (Saccharomyces cerevisiae 16, Sc16; Debaryomyces hansenii 25, Dh25), as well as S. cerevisiae subspecies boulardii (CNCM I-1079, Sb1079), were tested against ST by applying in vitro and in vivo tests. Adherence measurements to Caco-2 and HT29-MTX intestinal cells indicated that the two tested cheese yeasts presented a better adhesion than the probiotic Sb1079 as the control strain. Further, the Dh25 was the cheese yeast most likely to survive in the gastrointestinal tract. What is more, the modulation of the TransEpithelial Electrical Resistance (TEER) of differentiated Caco-2 cell monolayers showed the ability of Dh25 to delay the deleterious effects of ST. The influence of microorganisms on the in vivo model Caenorhabditis elegans was evaluated by measuring the longevity of the worm. This in vivo approach revealed that this yeast increased the worm’s lifespan and protected it against ST infection, confirming that this in vivo model can be useful for screening probiotic cheese yeasts.

show abstract

Clinical Efficacy Comparison Of Saccharomyces Boulardii And Lactic Acid As Probiotics In Acute Pediatric Diarrhea

Abstract: Objective: To compare the efficacy of Saccharomyces boulardii and lactic acid producing probiotics in addition to usual treatment regimen to cure diarrhea among children (6 months to 5 years of age).

Cited by 10 publications

References 12 publications

Qiweibaizhu Decoction Treats Diarrheal Juvenile Rats by Modulating the Gut Microbiota, Short-Chain Fatty Acids, and the Mucus Barrier

Qiweibaizhu Decoction Treats Diarrheal Juvenile Rats by Modulating the Gut Microbiota, Short-Chain Fatty Acids, and the Mucus Barrier

The Use of Probiotic with ORS and ORS Only in Children with Acute Diarrhea

Investigation into In Vitro and In Vivo Caenorhabditis elegans Models to Select Cheese Yeasts as Probiotic Candidates for their Preventive Effects against Salmonella Typhimurium

Contact Info

Product

Resources

About